# OnCo record irae-rheumatological (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-rheumatological/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-rheumatological" ;
  schema:name "Joint, muscle and other rheumatic side effects of checkpoint inhibitors"@en ;
  schema:alternateName "checkpoint inhibitor arthritis"@en, "ICI inflammatory arthritis"@en, "rheumatic irAEs"@en, "immune-related polymyalgia rheumatica"@en, "checkpoint inhibitor myositis"@en, "immune-related sicca syndrome"@en, "musculoskeletal irAEs"@en ;
  schema:description "Immunotherapy can cause joint pain and swelling, stiffness in the shoulders and hips, a dry mouth and eyes, or, rarely, muscle inflammation. Mild cases are treated with painkillers or anti-inflammatories; others need steroids and a rheumatologist, and immunotherapy often continues. Muscle weakness, trouble swallowing or breathlessness is urgent, because muscle inflammation can affect the heart."@en ;
  schema:url <https://onco.cc/protocols/irae-rheumatological/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "rheumatology" ;
  onco:related <https://onco.cc/protocols/irae-myocarditis/>, <https://onco.cc/protocols/irae-neurological/>, <https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/tocilizumab/>, <https://onco.cc/drugs/human-normal-immunoglobulin/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .